Home › Ventana Companion Diagnostics CAP/CLIA Lab Launches New Robust Prototype Assays
 

Keywords :   


Ventana Companion Diagnostics CAP/CLIA Lab Launches New Robust Prototype Assays

2014-06-04 13:03:18| drugdiscoveryonline News Articles

Ventana Medical Systems, Inc.(Ventana), a member of theRocheGroup, today announced the launch of three new companion diagnostic robust prototype assays (RPAs) for the detection of biomarkers PSMA, MDM2 and FGFR, offering biotech and pharmaceutical companies more options in exploring novel treatment options for patients with cancer

Tags: lab robust companion launches

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »